Clinical Trial: Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD)

U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07861152) titled 'Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD)' on Sept. 30.

Brief Summary: This study will test an experimental Regeneron drug called REGN24493 hereby referred to as "study drug" to see if it can help treat Graves' disease. Graves' disease is a condition where the immune system causes the thyroid gland to make too much thyroid hormone.

The main purpose of this study is to learn about the safety of REGN24493 and what side effects it might cause.

The study is looking at:

* What side effects REGN24493 might cause

* How much REGN24493 is in the blood at different t...